SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care ...
QuidelOrtho Corporation QDEL is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by solid third-quarter 2025 results, is expected to ...
SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) ...
QuidelOrtho, a result of a 2022 business combination, was a strong player in the COVID-19 testing sector, generating $1.3 billion in 2021 from COVID products. The company experienced a dramatic drop ...
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care ...
QuidelOrtho Corporation QDEL is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-half 2024 performance and its continued ...
QuidelOrtho Corporation QDEL is well-poised for growth in the coming quarters, courtesy of its product innovation aiding growth. The optimism led by a solid first-quarter 2023 performance and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results